The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The resolution was championed by the Endocrine Society, according to a press release ...

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

aDepartments of Surgery, New York University, New York, NY, USA bDepartment of Medicine, New York University, New York, NY, USA ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

aThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China bLuoyang Key Laboratory of Clinical Multiomics and Translational ...

Navitus, the nation’s first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...